Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Bären Apotheke Zytglogge | Galenica | Retail - Drugs without Grocery | $1.2M – $1.6M | 5× – 7× | |
| 16 VMS products from Orifarm | STADA | Retail - Drugs without Grocery | $8,170M – $10,590M | 10× – 13× | |
| Kinvara Pharmacy | McCabes Pharmacy | Retail - Drugs without Grocery | $3.8M – $4.6M | 7× – 8× | |
| HealthAid Limited and HealthAid America Inc. | PK Consumer Health | Retail - Drugs without Grocery | $340M – $400M | 11× – 13× | |
| Farmacie Italiane | Dr. Max Group | Retail - Drugs without Grocery | $78.5M – $106M | 6× – 8× | |
| Walgreen Co. | Sycamore Partners, Stefano Pessina and family | Retail - Drugs without Grocery | $26,000M – $35,000M | 5× – 7× | |
| Walgreens Boots Alliance, Inc. | Sycamore Partners, Stefano Pessina and family | Retail - Drugs without Grocery | $6,283M | 4× – 5× | |
| Farmacia Formaggia | Più Medical S.p.A. | Retail - Drugs without Grocery | $6.0M – $8.1M | 6× – 8× | |
| Rite Aid pharmacies and stores | CVS Pharmacy | Retail - Drugs without Grocery | $240M – $290M | 4× – 5× | |
| Rite Aid brand and related assets | Undisclosed | Retail - Drugs without Grocery | $120M – $140M | 4× – 5× |
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.